Carprieve 20mg Tablets

Country: New Zealand

Language: English

Source: Ministry for Primary Industries

Active ingredient:

carprofen

Available from:

Norbrook NZ Limited

INN (International Name):

carprofen

Composition:

carprofen 133.3 g/kg

Therapeutic area:

Analgesic

Authorization status:

ACVM Registered

Authorization date:

2002-03-04

Summary of Product characteristics

Carprieve 20 mg Tablets
Page
1
of
5
DRAFT LABEL _FEB 2024_
_BLISTER TEXT: _
WARNING
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
RVM
CARPRIEVE 20 MG TABLETS
20 mg CARPROFEN
Batch:
Expiry:
READ THE CARTON OR INSERT TEXT BEFORE USE
Carprieve 20 mg Tablets
Page
2
of
5
DRAFT LABEL
_FEB 2024_
_CARTON TEXT:_
_ _
WARNING
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY RESTRICTED VETERINARY MEDICINE
CARPRIEVE 20 MG TABLETS
NET CONTENTS:
100 x 20mg tablets
READ THE ENTIRE LABEL BEFORE USE
ACTIVE INGREDIENT:
Carprofen 133.3 mg/g
Each tablet contains 20mg Carprofen
INDICATIONS:
_CARPRIEVE TABLETS ARE A NON-STEROIDAL ANTI-INFLAMMATORY FORMULATION
WITH ANALGESIC ACTION. _
_THEY ARE INDICATED FOR ANALGESIA AND REDUCTION OF INFLAMMATION, FOR
EXAMPLE IN DEGENERATIVE _
_JOINT DISEASE OF THE DOG. _
DOSAGE & ADMINISTRATION:
For oral administration.
An initial dose of 2-4 mg/kg bodyweight / day is recommended to be
given in 2 equally divided doses.
This is provided by one _CARPRIEVE 20 MG_ _TABLET _per 20 to 10 kg
bodyweight, each morning and night.
After 7 days, dose may be reduced to 2 mg/kg/day as a single daily
dose, subject to clinical response.
Duration of treatment will depend on the response seen. Long-term
treatment should be under regular
veterinary supervision.
CONTRAINDICATIONS:
Do not administer other NSAIDs concurrently or within 24 hours of each
other.
Toxic effects can occur when drugs that are highly bound to plasma
proteins (such as NSAIDs) compete
with other highly bound drugs, leading to excess free drug(s) in
plasma.
Do not use where there is a possibility of gastro-intestinal
ulceration or bleeding; in animals suffering
from
cardiac,
hepatic
or
renal
disease;
or
where
there
is
evidence
of
a
blood
dyscrasia
or
hypersensitivity to the product.
Use in animals less than 6 weeks of age or in aged animals may involve
additional risk. If prescribed in
such cases, animals may require a reduced dosage and careful clinical
management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as